Cardiomyopathy Market, Global Outlook and Forecast 2022-2028

March 2022 | 68 pages | ID: CF613FFA94A4EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Cardiomyopathy in Global, including the following market information:

Global Cardiomyopathy Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Cardiomyopathy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Dilated cardiomyopathy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Cardiomyopathy include Array BioPharma, Boston Scientific, Cisbio, Covance, Critical Diagnostics, Mylan, Pfizer, Becton Dickinson and BG Medicine, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cardiomyopathy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cardiomyopathy Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Cardiomyopathy Market Segment Percentages, by Type, 2021 (%)

• Dilated cardiomyopathy
• Hypertrophic cardiomyopathy
• Restrictive cardiomyopathy

Global Cardiomyopathy Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Cardiomyopathy Market Segment Percentages, by Application, 2021 (%)

• Hospitals and diagnostic centers
• Ambulatory services centers

Global Cardiomyopathy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Cardiomyopathy Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Cardiomyopathy revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Cardiomyopathy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Array BioPharma
• Boston Scientific
• Cisbio
• Covance
• Critical Diagnostics
• Mylan
• Pfizer
• Becton Dickinson
• BG Medicine
• BioMerieux
• Bio-Rad

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Cardiomyopathy Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Cardiomyopathy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CARDIOMYOPATHY OVERALL MARKET SIZE

2.1 Global Cardiomyopathy Market Size: 2021 VS 2028
2.2 Global Cardiomyopathy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Cardiomyopathy Players in Global Market
3.2 Top Global Cardiomyopathy Companies Ranked by Revenue
3.3 Global Cardiomyopathy Revenue by Companies
3.4 Top 3 and Top 5 Cardiomyopathy Companies in Global Market, by Revenue in 2021
3.5 Global Companies Cardiomyopathy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Cardiomyopathy Players in Global Market
  3.6.1 List of Global Tier 1 Cardiomyopathy Companies
  3.6.2 List of Global Tier 2 and Tier 3 Cardiomyopathy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Cardiomyopathy Market Size Markets, 2021 & 2028
  4.1.2 Dilated cardiomyopathy
  4.1.3 Hypertrophic cardiomyopathy
  4.1.4 Restrictive cardiomyopathy
4.2 By Type - Global Cardiomyopathy Revenue & Forecasts
  4.2.1 By Type - Global Cardiomyopathy Revenue, 2017-2022
  4.2.2 By Type - Global Cardiomyopathy Revenue, 2023-2028
  4.2.3 By Type - Global Cardiomyopathy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Cardiomyopathy Market Size, 2021 & 2028
  5.1.2 Hospitals and diagnostic centers
  5.1.3 Ambulatory services centers
5.2 By Application - Global Cardiomyopathy Revenue & Forecasts
  5.2.1 By Application - Global Cardiomyopathy Revenue, 2017-2022
  5.2.2 By Application - Global Cardiomyopathy Revenue, 2023-2028
  5.2.3 By Application - Global Cardiomyopathy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Cardiomyopathy Market Size, 2021 & 2028
6.2 By Region - Global Cardiomyopathy Revenue & Forecasts
  6.2.1 By Region - Global Cardiomyopathy Revenue, 2017-2022
  6.2.2 By Region - Global Cardiomyopathy Revenue, 2023-2028
  6.2.3 By Region - Global Cardiomyopathy Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Cardiomyopathy Revenue, 2017-2028
  6.3.2 US Cardiomyopathy Market Size, 2017-2028
  6.3.3 Canada Cardiomyopathy Market Size, 2017-2028
  6.3.4 Mexico Cardiomyopathy Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Cardiomyopathy Revenue, 2017-2028
  6.4.2 Germany Cardiomyopathy Market Size, 2017-2028
  6.4.3 France Cardiomyopathy Market Size, 2017-2028
  6.4.4 U.K. Cardiomyopathy Market Size, 2017-2028
  6.4.5 Italy Cardiomyopathy Market Size, 2017-2028
  6.4.6 Russia Cardiomyopathy Market Size, 2017-2028
  6.4.7 Nordic Countries Cardiomyopathy Market Size, 2017-2028
  6.4.8 Benelux Cardiomyopathy Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Cardiomyopathy Revenue, 2017-2028
  6.5.2 China Cardiomyopathy Market Size, 2017-2028
  6.5.3 Japan Cardiomyopathy Market Size, 2017-2028
  6.5.4 South Korea Cardiomyopathy Market Size, 2017-2028
  6.5.5 Southeast Asia Cardiomyopathy Market Size, 2017-2028
  6.5.6 India Cardiomyopathy Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Cardiomyopathy Revenue, 2017-2028
  6.6.2 Brazil Cardiomyopathy Market Size, 2017-2028
  6.6.3 Argentina Cardiomyopathy Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Cardiomyopathy Revenue, 2017-2028
  6.7.2 Turkey Cardiomyopathy Market Size, 2017-2028
  6.7.3 Israel Cardiomyopathy Market Size, 2017-2028
  6.7.4 Saudi Arabia Cardiomyopathy Market Size, 2017-2028
  6.7.5 UAE Cardiomyopathy Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Array BioPharma
  7.1.1 Array BioPharma Corporate Summary
  7.1.2 Array BioPharma Business Overview
  7.1.3 Array BioPharma Cardiomyopathy Major Product Offerings
  7.1.4 Array BioPharma Cardiomyopathy Revenue in Global Market (2017-2022)
  7.1.5 Array BioPharma Key News
7.2 Boston Scientific
  7.2.1 Boston Scientific Corporate Summary
  7.2.2 Boston Scientific Business Overview
  7.2.3 Boston Scientific Cardiomyopathy Major Product Offerings
  7.2.4 Boston Scientific Cardiomyopathy Revenue in Global Market (2017-2022)
  7.2.5 Boston Scientific Key News
7.3 Cisbio
  7.3.1 Cisbio Corporate Summary
  7.3.2 Cisbio Business Overview
  7.3.3 Cisbio Cardiomyopathy Major Product Offerings
  7.3.4 Cisbio Cardiomyopathy Revenue in Global Market (2017-2022)
  7.3.5 Cisbio Key News
7.4 Covance
  7.4.1 Covance Corporate Summary
  7.4.2 Covance Business Overview
  7.4.3 Covance Cardiomyopathy Major Product Offerings
  7.4.4 Covance Cardiomyopathy Revenue in Global Market (2017-2022)
  7.4.5 Covance Key News
7.5 Critical Diagnostics
  7.5.1 Critical Diagnostics Corporate Summary
  7.5.2 Critical Diagnostics Business Overview
  7.5.3 Critical Diagnostics Cardiomyopathy Major Product Offerings
  7.5.4 Critical Diagnostics Cardiomyopathy Revenue in Global Market (2017-2022)
  7.5.5 Critical Diagnostics Key News
7.6 Mylan
  7.6.1 Mylan Corporate Summary
  7.6.2 Mylan Business Overview
  7.6.3 Mylan Cardiomyopathy Major Product Offerings
  7.6.4 Mylan Cardiomyopathy Revenue in Global Market (2017-2022)
  7.6.5 Mylan Key News
7.7 Pfizer
  7.7.1 Pfizer Corporate Summary
  7.7.2 Pfizer Business Overview
  7.7.3 Pfizer Cardiomyopathy Major Product Offerings
  7.7.4 Pfizer Cardiomyopathy Revenue in Global Market (2017-2022)
  7.7.5 Pfizer Key News
7.8 Becton Dickinson
  7.8.1 Becton Dickinson Corporate Summary
  7.8.2 Becton Dickinson Business Overview
  7.8.3 Becton Dickinson Cardiomyopathy Major Product Offerings
  7.8.4 Becton Dickinson Cardiomyopathy Revenue in Global Market (2017-2022)
  7.8.5 Becton Dickinson Key News
7.9 BG Medicine
  7.9.1 BG Medicine Corporate Summary
  7.9.2 BG Medicine Business Overview
  7.9.3 BG Medicine Cardiomyopathy Major Product Offerings
  7.9.4 BG Medicine Cardiomyopathy Revenue in Global Market (2017-2022)
  7.9.5 BG Medicine Key News
7.10 BioMerieux
  7.10.1 BioMerieux Corporate Summary
  7.10.2 BioMerieux Business Overview
  7.10.3 BioMerieux Cardiomyopathy Major Product Offerings
  7.10.4 BioMerieux Cardiomyopathy Revenue in Global Market (2017-2022)
  7.10.5 BioMerieux Key News
7.11 Bio-Rad
  7.11.1 Bio-Rad Corporate Summary
  7.11.2 Bio-Rad Business Overview
  7.11.3 Bio-Rad Cardiomyopathy Major Product Offerings
  7.11.4 Bio-Rad Cardiomyopathy Revenue in Global Market (2017-2022)
  7.11.5 Bio-Rad Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Cardiomyopathy Market Opportunities & Trends in Global Market
Table 2. Cardiomyopathy Market Drivers in Global Market
Table 3. Cardiomyopathy Market Restraints in Global Market
Table 4. Key Players of Cardiomyopathy in Global Market
Table 5. Top Cardiomyopathy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Cardiomyopathy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Cardiomyopathy Revenue Share by Companies, 2017-2022
Table 8. Global Companies Cardiomyopathy Product Type
Table 9. List of Global Tier 1 Cardiomyopathy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cardiomyopathy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Cardiomyopathy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Cardiomyopathy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Cardiomyopathy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Cardiomyopathy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Cardiomyopathy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Cardiomyopathy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Cardiomyopathy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Cardiomyopathy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Cardiomyopathy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Cardiomyopathy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Cardiomyopathy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Cardiomyopathy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Cardiomyopathy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Cardiomyopathy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Cardiomyopathy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Cardiomyopathy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Cardiomyopathy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Cardiomyopathy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Cardiomyopathy Revenue, (US$, Mn), 2023-2028
Table 30. Array BioPharma Corporate Summary
Table 31. Array BioPharma Cardiomyopathy Product Offerings
Table 32. Array BioPharma Cardiomyopathy Revenue (US$, Mn), (2017-2022)
Table 33. Boston Scientific Corporate Summary
Table 34. Boston Scientific Cardiomyopathy Product Offerings
Table 35. Boston Scientific Cardiomyopathy Revenue (US$, Mn), (2017-2022)
Table 36. Cisbio Corporate Summary
Table 37. Cisbio Cardiomyopathy Product Offerings
Table 38. Cisbio Cardiomyopathy Revenue (US$, Mn), (2017-2022)
Table 39. Covance Corporate Summary
Table 40. Covance Cardiomyopathy Product Offerings
Table 41. Covance Cardiomyopathy Revenue (US$, Mn), (2017-2022)
Table 42. Critical Diagnostics Corporate Summary
Table 43. Critical Diagnostics Cardiomyopathy Product Offerings
Table 44. Critical Diagnostics Cardiomyopathy Revenue (US$, Mn), (2017-2022)
Table 45. Mylan Corporate Summary
Table 46. Mylan Cardiomyopathy Product Offerings
Table 47. Mylan Cardiomyopathy Revenue (US$, Mn), (2017-2022)
Table 48. Pfizer Corporate Summary
Table 49. Pfizer Cardiomyopathy Product Offerings
Table 50. Pfizer Cardiomyopathy Revenue (US$, Mn), (2017-2022)
Table 51. Becton Dickinson Corporate Summary
Table 52. Becton Dickinson Cardiomyopathy Product Offerings
Table 53. Becton Dickinson Cardiomyopathy Revenue (US$, Mn), (2017-2022)
Table 54. BG Medicine Corporate Summary
Table 55. BG Medicine Cardiomyopathy Product Offerings
Table 56. BG Medicine Cardiomyopathy Revenue (US$, Mn), (2017-2022)
Table 57. BioMerieux Corporate Summary
Table 58. BioMerieux Cardiomyopathy Product Offerings
Table 59. BioMerieux Cardiomyopathy Revenue (US$, Mn), (2017-2022)
Table 60. Bio-Rad Corporate Summary
Table 61. Bio-Rad Cardiomyopathy Product Offerings
Table 62. Bio-Rad Cardiomyopathy Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Cardiomyopathy Segment by Type in 2021
Figure 2. Cardiomyopathy Segment by Application in 2021
Figure 3. Global Cardiomyopathy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Cardiomyopathy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Cardiomyopathy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Cardiomyopathy Revenue in 2021
Figure 8. By Type - Global Cardiomyopathy Revenue Market Share, 2017-2028
Figure 9. By Application - Global Cardiomyopathy Revenue Market Share, 2017-2028
Figure 10. By Region - Global Cardiomyopathy Revenue Market Share, 2017-2028
Figure 11. By Country - North America Cardiomyopathy Revenue Market Share, 2017-2028
Figure 12. US Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Cardiomyopathy Revenue Market Share, 2017-2028
Figure 16. Germany Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 17. France Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Cardiomyopathy Revenue Market Share, 2017-2028
Figure 24. China Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 28. India Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Cardiomyopathy Revenue Market Share, 2017-2028
Figure 30. Brazil Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Cardiomyopathy Revenue Market Share, 2017-2028
Figure 33. Turkey Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Cardiomyopathy Revenue, (US$, Mn), 2017-2028
Figure 37. Array BioPharma Cardiomyopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Boston Scientific Cardiomyopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Cisbio Cardiomyopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Covance Cardiomyopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Critical Diagnostics Cardiomyopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Mylan Cardiomyopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Pfizer Cardiomyopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Becton Dickinson Cardiomyopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. BG Medicine Cardiomyopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. BioMerieux Cardiomyopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Bio-Rad Cardiomyopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)